Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2022

View Archived Issues

NLRP4 mutations predict anti-PD-L1 treatment response in patients with NSCLC

Shengke Pharmaceuticals discovers FLT inhibitors

New lysine-specific demethylase 5B inhibitors identified at FibroGen

New G protein-coupled receptor 52 agonists synthesized at Heptares Therapeutics

Sichuan Good Doctor Panxi Pharmaceutical describes new wound-healing polypeptides

TIMP-1 and CKM are biomarkers of treatment response in DMD

New rat model may shed light on mechanisms behind CSVD pathogenesis

New GSK-3 inhibitors patented by Ramot at Tel Aviv University, Bar-Ilan University

RGX-202 improves muscle function and dystrophic muscle pathology in mice

Blood stem cells treat brain disease after transplant

Discovery of novel S1PR2 ligands as tracers for neuroimaging

PepGen presents promising preclinical data for PGN-EDO51

ETC-642 increases plasma HDL and protects mice from sepsis

Sanofi and Seagen to develop and commercialize antibody-drug conjugates for cancer targets

Oppilotech partners with Evariste on first-in-class antibacterial program

Sareum receives final preclinical toxicology report for SDC-1801

In vivo pharmacokinetic data confirm BETR-001 bioavailability in target brain tissue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.